文献速递头颈外科

软腭鳞状细胞癌患者的预后因素

Prognostic factors in patients with soft palate squamous cell carcinoma.
PubMed 文献 · Head Neck · 2019-01-12

研究纳入1997至2012年在本机构接受治疗的156例初治软腭及悬雍垂鳞状细胞癌患者,中位年龄58岁,分析临床、血液学及治疗特征的预后价值。5年总生存率和无进展生存率分别为41%和37%。单因素分析显示T3-T4期、N2-N3期及中性粒细胞计数>7 g/L与较差的总生存率和无进展生存率相关。

要点

  • 软腭鳞癌患者5年总生存率和无进展生存率分别为41%和37%。
  • T3-T4期、N2-N3期与较差的总生存率和无进展生存率相关。
  • 中性粒细胞计数>7 g/L与较差的总生存率和无进展生存率相关。

核心结论

  • 在软腭鳞状细胞癌患者中,炎症生物标志物与总生存率相关。

研究设计与样本

  • 研究收集1997年至2012年在本机构接受治疗的既往未经治疗的软腭及悬雍垂鳞状细胞癌患者,共156例,中位年龄58岁。
  • 分析临床、血液学及治疗特征的预后价值。

主要发现

  • 156例患者中,饮酒者占71%,吸烟者占91%,19%的患者存在同时性癌症。
  • 一线治疗为放化疗者58例(37%),单纯放疗者60例(39%),手术者17例(11%),诱导化疗者21例(14%)。
  • 5年实际总生存率和无进展生存率分别为41%和37%。
  • 单因素分析显示,T3-T4期对比T1-T2期、N2-N3期对比N0-N1期及中性粒细胞计数>7 g/L与较差的总生存率和无进展生存率相关(P < .05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC). METHODS: Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined. RESULTS: We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front-line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3-T4 vs T1-T2 stage, N2-N3 vs N0-N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05). CONCLUSION: In patients with soft palate SCC, inflammation biomarkers were associated with OS.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Schernberg A, Canova C, Blanchard P, et al. Prognostic factors in patients with soft palate squamous cell carcinoma. Head Neck. 2019. PMID: 30636178. doi:10.1002/hed.25598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。